pomalidomide,dexamethasone,abemaciclib,ixazomib,selinexor,enasidenib,erdafitinib,belantamab mafodotin,daratumumab,cobimetinib,venetoclax
roche,takeda,bms,eli lilly,servier,janssen,abbvie,gsk,karyopharm therapeutics
rrmm presenter shaji kumar detailed clinical results using a "precis. med." approach using genomics (mydrug) sub-protocol c1 targeting ras mutations. pts with rrmm were given mek inhibitor cobimetinib in combination with ipd which is determined safe in high-risk pts. #ims2022 
To cure myeloma by fostering research, education and excellence in clinical care worldwide.